UC Irvine

UC Irvine Previously Published Works

Title

Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.

Permalink https://escholarship.org/uc/item/67k0p6jk

Journal Hepatology, 76(1) Authors

Serper, Marina Parikh, Neehar Thiele, Grace <u>et al.</u>

Publication Date 2022-07-01

DOI 10.1002/hep.32313

Peer reviewed



HHS Public Access

Author manuscript *Hepatology*. Author manuscript; available in PMC 2023 November 15.

Published in final edited form as:

Hepatology. 2022 July ; 76(1): 251–274. doi:10.1002/hep.32313.

Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Marina Serper^{1,2,3}, Neehar D. Parikh⁴, Grace Thiele¹, Nadia Ovchinsky⁵, Shivang Mehta⁶, Alexander Kuo⁷, Chanda Ho⁸, Fasiha Kanwal^{9,10,11}, Michael Volk¹², Sumeet K. Asrani¹³, Marwan S. Ghabril¹⁴, John R. Lake¹⁵, Raphael B. Merriman¹⁶, Timothy R. Morgan¹⁷, Elliot B. Tapper^{4,18}

¹Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

²Section of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA

³Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania, USA

⁴Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA

⁵Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital at Montefiore–Albert Einstein College of Medicine, Bronx, New York, USA

⁶Hepatology, Baylor All Saints, Fort Worth, Texas, USA

⁷Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, California, USA

⁸Department of Transplantation, California Pacific Medical Center, San Francisco, California, USA

⁹Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA

¹⁰Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA

CONFLICTS OF INTEREST

Correspondence: Elliot Tapper, Division of Gastroenterology and Hepatology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA, etapper@umich.edu.

AUTHOR CONTRIBUTIONS

Concept: Marina Serper, and Elliot B. Tapper. *Data acquisition:* Marina Serper, Elliot B. Tapper, Neehar D. Parikh, Grace Thiele, Nadia Ovchinisky, Shivang Mehta, Alexander Kuo, Chanda Ho, Fasiha Kanwal, Michael Volk, Sumeet K. Asrani, Marwan S. Ghabril, John R. Lake, Raphael B. Merriman, and Timothy R. Morgan. *Writing:* Marina Serper, Elliot B. Tapper, Neehar D. Parikh, and Grace Thiele. *Revision:* Nadia Ovchinisky, Shivang Mehta, Alexander Kuo, Chanda Ho, Fasiha Kanwal, Michael Volk, Sumeet K. Asrani, Marwan S. Ghabril, John R. Lake, Raphael B. Merriman, and Timothy R. Morgan.

Dr. Serper consults for Gilead. Dr. Parikh advises Genentech, Bayer, and Eisai. Dr. Volk consults and is on the speakers' bureau for Bausch. Dr. Lake consults for HepQuant and Micromatrix. He received grants from Cymabay. Dr. Morgan received grants from Genfit, AbbVie, and Gilead.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

¹¹Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA

¹²Division of Gastroenterology and Transplantation Institute, Loma Linda University, Loma Linda, California, USA

¹³Hepatology, Baylor University Medical Center, Dallas, Texas, USA

¹⁴Indiana University School of Medicine, Indianapolis, Indiana, USA

¹⁵Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA

¹⁶California Pacific Medical Center, San Francisco, California, USA

¹⁷VA Long Beach Healthcare System, Long Beach, California, USA

¹⁸Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA

Abstract

Background and Aims: HCC is a leading cause of mortality in patients with advanced liver disease and is associated with significant morbidity. Despite multiple available curative and palliative treatments, there is a lack of systematic evaluation of patient-reported outcomes (PROs) in HCC.

Approach and Results: The American Association for the Study of Liver Diseases Practice Metrics Committee conducted a scoping review of PROs in HCC from 1990 to 2021 to (1) synthesize the evidence on PROs in HCC and (2) provide recommendations on incorporating PROs into clinical practice and quality improvement efforts. A total of 63 studies met inclusion criteria investigating factors associated with PROs, the relationship between PROs and survival, and associations between HCC therapy and PROs. Studies recruited heterogeneous populations, and most were cross-sectional. Poor PROs were associated with worse prognosis after adjusting for clinical factors and with more advanced disease stage, although some studies showed better PROs in patients with HCC compared to those with cirrhosis. Locoregional and systemic therapies were generally associated with a high symptom burden; however, some studies showed lower symptom burden for transarterial radiotherapy and radiation therapy. Qualitative studies identified additional symptoms not routinely assessed with structured questionnaires. Gaps in the literature include lack of integration of PROs into clinical care to guide HCC treatment decisions, unknown impact of HCC on caregivers, and the effect of palliative or supportive care quality of life and health outcomes.

Conclusion: Evidence supports assessment of PROs in HCC; however, clinical implementation and the impact of PRO measurement on quality of care and longitudinal outcomes need future investigation.

INTRODUCTION

HCC is the fourth most common cause of cancer death and has the second highest casefatality rate among all cancers.^[1] Treatment algorithms for HCC are complex and vary greatly in clinical settings. Depending on the cancer stage, a patient may undergo therapies

that are curative (resection, ablation, liver transplantation) or palliative (locoregional, systemic, best supportive); and often, several of these therapies are used in sequence or combination. These care strategies produce diverse symptom profiles and have a variable psychosocial impact over time. In understanding the full scope of how a method of treatment will affect the outcome of a patient with HCC, it is imperative to account for the impact of a given treatment modality on patient-reported outcomes (PROs), defined as any report of the status of a patient's health condition that comes directly from the patient.^[2] Multiple tools are available to assess the well-being of affected patients, however, comprehensive summaries of PROs in HCC are lacking.

Despite the significant impact of HCC and its therapies on PROs, they are rarely measured in routine clinical practice to guide treatment decisions and symptom management or inform quality improvement efforts. PROs serve at least three practical purposes. First, routine PRO collection allows systematic evaluation of where improvements are needed in patient experience, patient educational needs, and supportive care, informing navigation programs and the goals of clinical follow-up. Second, PROs may play a role in guiding decision-making regarding treatment selection and stopping rules.^[3] Finally, PROs can be used to define treatment effectiveness for regulatory purposes. However, before incorporating PRO measurement into HCC care, the first step is to identify key themes of value to patients.

The American Association for the Study of Liver Diseases Practice Metrics Committee used a two-step process that includes scoping reviews and focus groups to identify candidate PROs in HCC care.^[4] As previously examined for cirrhosis care,^[4,5] we conducted a scoping review of the available evidence of PROs in HCC. Our overall objectives were to (1) synthesize the available evidence on PROs in HCC and (2) provide guidance on incorporating PROs into clinical practice and quality improvement efforts in HCC care. PROs and health-related quality of life (HRQOL) are often synonymous in the literature; this review will use *PROs* and *HRQOL* interchangeably.^[6]

MATERIALS AND METHODS

We aimed to characterize PROs used in evaluation and management of patients with HCC. To do so, we conducted a scoping review, a variant of a systematic review that seeks to identify and map the concepts within a large body of evidence. When the body of literature is large, heterogeneous, and without a prior comprehensive review, scoping review methodology may be more appropriate than a systematic review.^[7]

Search strategy

We searched four databases: PsycINFO, PubMed, Embase, and Cumulative Index to Nursing and Allied Health Literature, from inception to October 2021. The details of the search strategy applied to each database are provided in Table S1. Search terms were compiled from three major categories: names of already published PRO measures (e.g., Short Form 36 [SF-36], Functional Assessment of Cancer Therapy, Hepatobiliary [FACT-Hep], European Organisation for Research and Treatment of Cancer-Quality of Life [EORTC-QOL], EuroQoL–5 Dimensions [EQ-5D]), more general PRO terminology (e.g., *patient satisfaction, HRQOL, QOL*), and disease-specific terms (e.g., *liver cell carcinoma, HCC*,

hepatoma). Studies related to bile duct carcinoma and cholangiocarcinoma were excluded. All results were compiled using the Rayyan QCRI web-based application.^[8]

Study selection

Eligibility criteria—Studies were selected if they reported quantitative PRO measures provided at a granular level (at the level of domains or subscales) before or following a standard therapeutic intervention for HCC or if they provided a qualitative PRO analysis. To be included in the scoping review, studies with quantitative PRO measures had to provide sufficient details for descriptive statistics (e.g., mean, standard deviation) and information specific to HCC (e.g., studies reporting aggregate PROs of multiple malignancies were excluded). We excluded studies of children (<18 years), animals, non-English publications, case reports, abstracts, those including non-standard-of-care therapies (e.g., herbals), and those that only included patients after liver transplantation.

Review—All titles and abstracts were independently reviewed by two members of the Practice Metrics Committee for relevance. Full-text documents were then retrieved, reviewed by two reviewers, and subsequently included in the final review or excluded based on the eligibility criteria. All disagreements between reviewers were arbitrated by a third reviewer. Studies were excluded in cases of insufficient details in the methods or results if the cohorts overlapped with previously published literature. Studies validating or translating questionnaires into other languages were also excluded. Figure S1 shows the preferred reporting items for systematic reviews and meta-analyses flow diagram for study inclusion.

Data extraction and analysis

Extracted information included study design, PRO measure(s), therapeutic intervention(s), sample size, disease stage, system of cancer staging, prior therapy (if applicable), study aims, and prognostic factors (e.g., survival) identified.

Studies providing granular data from PRO measures over time were further analyzed using heat maps created in Microsoft Excel. Each study was categorized by which PRO measure(s) it reported. Baseline and longitudinal data for each subscale or domain were extracted if applicable. Longitudinal data were color-coded according to whether they demonstrated a measured improvement or deterioration and further coded according to whether that change was clinically and/or statistically significant (as reported by the individual studies). Clinical significance was determined using previously reported minimal clinically important differences for each PRO measurement. The heat map was arranged according to HCC therapy, from curative to palliative.

RESULTS

Overview

After the initial search terms and selection criteria were applied, a total of 63 articles met inclusion criteria (Figure S1). We found multiple validated questionnaires (e.g., SF-3 6, FACT-Hep, EORTC-QOL) used to assess multiple domains of HRQOL. HRQOL is a subset

of PROs that includes social, emotional, functional, and physical well-being as well as general, liver disease–specific, and hepatobiliary cancer symptoms (Figure 1).

Physical PROs in HCC

Patients with HCC experienced a high burden of physical symptoms that were often driven by their underlying cirrhosis and liver function (Table 1). In a single center in Korea, Ryu et al. identified four major symptom clusters: (1) pain appetite, (2) fatigue-related, (3) gastrointestinal, and (4) itching-constipation.^[9] High symptom burden was significantly associated with poor functional status and worse global HRQOL on the FACT-Hep scale. ^[10] Chung et al. found that fatigue and sleep disturbance were the most severe symptoms experienced by patients with HCC.^[11] Several studies showed that the severity of the underlying liver function and tumor burden was associated with HRQOL. Li et al. found that HRQOL correlated best with indices of liver function (such as albumin and bilirubin) irrespective of tumor stage among a cohort of patients largely with Child A cirrhosis. ^[12] Qiao et al. found that tumor stage was strongly and inversely associated with FACT-Hep scores, particularly for physical and emotional well-being.^[13] Hsu et al. found that nutritional status was a crucial determinant of HRQOL.^[14] Two studies comparing PROs among HCC and matched controls with chronic liver disease found conflicting results. Kondo et al. reported that liver disease severity (i.e., albumin level or presence of ascites), not the presence or absence of recurrent HCC, in patients treated with radiofrequency ablation (RFA) was associated with HRQOL.^[15] However, Bianchi et al. found that patients with HCC reported more bodily pain and poor sleep quality compared to patients with cirrhosis.[10]

Psychosocial and psychological factors affecting PROs in HCC

Patients with HCC were found to experience a substantial burden of symptoms within psychological and social domains (Table 2). Depression and anxiety were very common^[16] and became more prevalent after liver-directed therapy.^[17] Hansen et al. used the Memorial Symptoms Assessment Scale to evaluate the presence, frequency, and severity of 32 symptoms among 18 patients with advanced HCC receiving palliative locoregional, systemic therapy, and radiation who were followed monthly for 6 months.^[18] The most distressing symptoms were lack of energy, problems with sexual interest or activity, worrying, and feeling irritable. Fan et al. found that HCC was associated with worse global HRQOL as well as lower physical, cognitive, and social functioning but higher emotional functioning compared with population norms.^[19]

In studies that compared psychosocial domains in patients with HCC to matched controls with cirrhosis, patients with HCC often reported higher levels of functioning. Steel et al. compared HRQOL in HCC prior to treatment to patients with cirrhosis without HCC and the general population using FACT-Hep. Patients with HCC reported better social and family well-being than those with cirrhosis^[20] but worse sexual function and morbidity.^[21] Palmieri et al. found that patients with HCC had higher scores for general health and vitality but lower scores for social functioning and role limitations than those with cirrhosis.^[22] Moore et al. reported on posttraumatic growth (a concept synonymous with resilience after

traumatic events) in 202 patients with HCC and did not find any changes over time or associations with HRQOL.^[23]

Prognostic significance of PROs in HCC

Associations between HRQOL and survival were examined in seven studies (Table 3). Bonnetain et al.^[24] pooled data from two randomized multicenter trials comparing tamoxifen with palliative care for untreatable HCC and as add-on therapy for transarterial chemoembolization (TACE). HRQOL, defined by the Spitzer QOL Index, was positively associated with survival after adjusting for tumor size, alpha-fetoprotein (AFP), and liver disease severity. Sternby Eilard et al. investigated whether the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) and Hepatocellular Carcinoma-18 (HCC-18) HRQOL questionnaires could improve prognostication of HCC survival in a prospective study of 185 previously treated patients who had residual disease.^[25] Combining the HCC-18 nutrition scale with Barcelona Clinic Liver Cancer (BCLC) staging, tumor-node-metastasis stage, Eastern Cooperative Oncology Group (ECOG) performance status, and/or AFP improved survival prediction, as did adding the C30 fatigue and HCC-18 nutrition scales to the Cancer of the Liver Italian Program score.^[26] In a prospective single-center study of 242 patients, Gmür et al. showed that the FACT-Hep questionnaire improves prognostication beyond ECOG performance status.^[27] Li et al. investigated the prognostic significance of OLO-C30, QLQ-HCC-18, and C30/HCC-18 index scores in patients with newly diagnosed HCC of various stages.^[28] A higher symptom burden on the QLQ-C30 index and the QLO-HCC-18 was associated with higher adjusted mortality. Kim et al. evaluated EORTC QLQ-30, QLQ-HCC-18, and FACT-Hep in a Korean cohort of 300 patients and found that EORTC role functioning and the hepatobiliary cancer subscale of the FACT-Hep enhanced the prediction of 1-year survival when added to conventional cancer staging systems (American Joint Committee on Cancer and BCLC). The role functioning and appetite loss subscales in the EORTC QLQ-C30 were associated with disease progression and 1-year survival in multivariable analysis.^[29] In a cohort of 735 patients with HCC, Deng et al. found that female sex, Black race, current tobacco use, and comorbidities were associated with poor physical and/or mental HRQOL on the Short Form 12 (SF-12). Patients with low or medium physical component scores compared to high scores had lower adjusted survival. ^[30] Meier et al. prospectively evaluated the HRQOL of 130 patients with treatment-naive HCC using the QLQ-C30 and the QLQ-HCC-18 and found that in addition to BCLC stage and HCC-directed treatment, a domain of HRQOL called role function (e.g., ability to perform daily activities, leisure-time activities, and work) was associated with survival.^[31] In sum, although underlying disease severity often accounted for differences in PROs in cross-sectional studies, PROs improved predictions of mortality when added to medical factors.

Qualitative studies of PROs in HCC

We found seven qualitative studies. The dominant themes elicited are summarized in Figure 2. Gill et al. conducted an online survey with open-ended questions among 256 patients with HCC in 13 countries, 50% of whom underwent resection or transplant.^[32] Respondents were asked for three words that best described their feelings regarding HCC on diagnosis. The five most common words were *fear*, *worry*, *scared*, *anxiety*, and *shock*. Respondents

reported worsened concentration (47%), physical condition (44%), and mental condition (36%). Of all treatment modalities (liver-directed and systemic, excluding surgery), 37% reported TACE and 25% reported sorafenib to be the most challenging therapies. Overall, 60% reported permanently stopping work due to side effects. Fan and Eiser conducted 33 semistructured interviews among patients at various HCC stages treated with resection, TACE, and systemic therapy. Patients endorsed physical symptoms (weakness, anorexia, flatulence) and psychosocial stress (depression, poor sleep, worry, fear of death) as well as some positive changes (more focus on self-care). Patients reported social strain: inability to work, dependence, and adding stress to family with respect to uncertainties regarding the results of upcoming imaging tests or changes in the treatment plan.^[33] Hansen et al. prospectively evaluated HCC symptoms among 14 patients with HCC beyond Milan criteria for up to 6 months.^[34] Major themes elicited were hope and hopelessness (even in the same patient) and fear in anticipation of liver scans. Patients reported distress caused by limited knowledge of the prognosis, HCC etiology, and treatment options including transplant. Not having transplant as an option was painful for some and relieving for others. Some expressed regret over treatment and severe dislike of sorafenib. Kaiser et al. conducted 10 semistructured interviews of patients with HCC treated with sorafenib and found that gastrointestinal symptoms (diarrhea, abdominal pain, bloating, anorexia, nausea) were the most common and important to the patients, followed by fatigue and skin toxicity.^[35] Lo et al. conducted a stated preference study with 150 European patients with HCC to determine their perspectives on therapy.^[36] Patients preferred one-time therapies and oral therapies to infusions. Overall survival benefits were the most important predictor of treatment selection; however, patients would trade survival time to reduce the risk of hypertension, gastrointestinal effects, and fatigue. Lee^[37] elicited negative themes (depressive symptoms and spiritual distress) and positive themes (acceptance, connectedness to someone/thing, satisfaction with and meaningfulness in life). The main subthemes were exhaustion, regret, stigma, sadness, anger, fear, anguish, nervousness, pain, helplessness, ambivalence, hopelessness, irritability, frustration, neglect, guilt, being punished by God, and abandonment. Patel et al. found in interviews with 25 patients with BCLC stages that the most prevalent and disturbing experiences were fatigue, frustration, fear, and depression. ^[38] Abdominal pain and skin complaints were common and disturbing for BCLC-C patients.

Effects of HCC therapy on PROs-registration trials

PROs have been assessed in several clinical trials of unresectable HCC (Table 4). In IMBRAVE150, atezolizumab–bevacizumab was associated with a reduced risk of deterioration on all QLQ-C30 generic cancer symptom scales (appetite loss, diarrhea, fatigue, pain) and several QLQ-HCC-18 disease-specific symptom scales (fatigue, pain) when compared to sorafenib. Atezolizumab–bevacizumab versus sorafenib was associated with delayed deterioration of global HRQOL (11.2 vs. 3.6 months), physical functioning (13.1 vs. 4.9 months), and role functioning (9.1 vs. 3.6 months).^[39,40] In the Phase 3 REFLECT trial (lenvatinib vs. sorafenib), baseline HRQOL scores were similar and declined in both groups following initiation of treatment. Time to clinically meaningful deterioration in role functioning, pain, and diarrhea (QLQ-C30), nutrition, and body image (QLQ-HCC-18), and EQ-5D Visual Analogue Scale (VAS) was nominally shorter with sorafenib compared to lenvatinib.^[41,42]

HRQOL has been evaluated for ramucirumab, nivolumab and ipilumimab, and pembrolizumab. In the Phase 3 REACH-2 study, ramucirumab was compared to placebo in patients with unresectable HCC who had received first-line therapy. The median time to deterioration in FACT Hepatobiliary Symptom Index-8 (FHSI-8) total score was prolonged

deterioration in FACT Hepatobiliary Symptom Index-8 (FHSI-8) total score was prolonged with ramucirumab (3.3 vs. 1.9 months). Time to deterioration in EQ-5D score was not significantly different between ramucirumab and placebo.^[43,44] In the Phase 2 study comparing three different doses of nivolumab and ipilimumab for unresectable HCC in the second-line setting, the high-dose arms with the most efficacious effect on progression-free survival resulted in superior HRQOL compared to lower doses based on EQ-5D VAS and utility index.^[45] In the Phase 3 KEYNOTE-240 study (pembrolizumab vs. placebo), from baseline to week 12 changes in both EORTC QLQ-C30 and QLQ-HCC-18 scores and time to deterioration were similar for both arms.^[46]

Two Phase 3 trials have evaluated radioembolization versus sorafenib for the treatment of unresectable HCC. In the SARAH trial, the global health status sub-score was significantly better in the radioembolization (Y90) group than in the group with sorafenib.^[47] In the SIRVENIB trial, there were no significant differences in the EQ-5D index between the radioembolization and sorafenib groups throughout the study in either the intention-to-treat or per-protocol populations; however, radioembolization had fewer Grade 3 or higher adverse events.[48]

Effects of HCC therapy on PROs—real-world evidence

The longitudinal changes in PROs associated with therapy in real-world settings are detailed in Figures 3 and 4 and Table 4.^[49–72] Studies were heterogeneous with respect to eligibility criteria, methods for tumor staging, PRO measures, timing of assessments, and duration of follow-up. However, generally, hepatic resection and ablative therapies (e.g., curative) were associated with clinically significant symptom improvement, although there was some heterogeneity across studies (minimally important differences are shown in Figure 3). In the Functional Assessment of Chronic Illness Therapy questionnaire (Figure 3), locoregional therapy (largely TACE) was generally associated with symptom deteriorations, as were sorafenib and best supportive care. When assessed with SF-12, SF-36, and EORTC QLQ instruments (Figure 4A), curative therapies, TACE, and combination TACE/RFA were largely associated with symptom improvements, whereas sorafenib was associated with shorter-term symptom improvement and longer-term worsening. The EORTC questionnaire showed short-term symptom worsening and subsequent symptom stability with TACE (Figure 4B). Data on transarterial radioembolization (TARE)/90-yttrium therapy are emerging and suggest that TARE is well tolerated in unresectable HCC, can help maintain HRQOL for longer compared to sorafenib, and is associated with smaller HRQOL decrements and symptoms than TACE, although studies are largely small, heterogeneous, and with variable comparison groups.^[50,68–71] Data on radiotherapy are limited; a study by Iwata et al. showed that proton radiotherapy was associated with HRQOL preservation as measured by EORTC at 1 year among patients age 80 and older.^[72]

DISCUSSION

HCC is associated with significant morbidity that impacts PROs stemming from several factors, including the presence of cancer itself, the severity of underlying cirrhosis, and adverse effects associated with HCC therapy. In this scoping review, we summarize the current state of knowledge about PROs in HCC with the aim of characterizing PROs that could better inform patient–clinician discussions, guide tailored treatment plans, and lead to quality improvement in clinical management of HCC.

Central themes

We found that several important themes dominate the literature on PROs in HCC care. First, the largest contribution to PRO burden in patients with HCC is related to cirrhosis and other physical and psychiatric comorbidities rather than HCC itself. The most common symptoms independently related to HCC include bodily pain, fatigue, sexual dysfunction, and sleep disturbance, highlighting areas of need for symptom management in this population. Second, the severity of the underlying liver disease is a crucial determinant of poor PROs. Third, PROs are correlated with several patient-related factors, which can be interrelated with cirrhosis/HCC, including functional status and nutritional status.^[73] Fourth, HRQOL is often independently associated with survival in patients with HCC, highlighting their potential role and value in treatment monitoring. Fifth, qualitative studies elicit concerns such as feelings of fear, stigma, specific symptoms related to systemic therapy, trade-offs between symptom burden and efficacy, as well as positive themes such as hope, acceptance, life meaning, and satisfaction. Finally, curative therapies are associated with improvement in PROs, whereas, as starkly depicted in Figures 3 and 4, palliative therapies are generally associated with deterioration of PROs, although the time course of PRO deterioration varies depending on treatment (locoregional vs. systemic). While many of the included studies examined HRQOL associated with sorafenib, several recent registration trials show that more efficacious therapies, particularly atezolizumab and bevacizumab, result in a superior HRQOL.

Persistent gaps

There are several gaps identified in our review that warrant attention in future studies. First, there is a paucity of high-quality data for certain populations of patients with HCC; data for locoregional therapies (TACE/TARE) and radiotherapy are still emerging. Many of the studies included are small and consisted of single-center cohorts that lacked power for meaningful subgroup analyses. Setting appropriate expectations of symptoms may help patients cope with side effects and better choose among treatment regimens with similar therapeutic efficacy; this is an area ripe for future study. HCC registration trials show efficacy and decreased adverse event burden with improvement in PROs; however, realworld data in patients receiving systemic therapy are still lacking. Second, the instruments to measure PROs can vary widely in their symptom assessment. Generic instruments such as the SF-36 and Short Form 8 have been broadly applied across health conditions and are well validated; however, may miss disease-specific instruments, such as the FACT-Hep or QLQ-HCC-18, include HCC-specific measures but have fewer data to support their validity.

For example, only a small proportion of patients in the FACT-Hep derivation and validation studies had HCC (7% and 19%, respectively), and critical parameters such as minimal important differences have not been established for the QLQ-HCC-18.^[75,76] Qualitative studies highlighted a myriad of patient symptoms and concerns that may not be adequately captured by existing instruments. Further validation of disease-specific PRO instruments across health states, with more granular accounting for underlying liver disease, sex, and other sociodemographic factors, is necessary to ensure that the instruments capture the breadth of symptoms and concerns that patients with HCC experience.

Opportunities

Broadly, the opportunities in PRO research apply to further investigation and implementation. First, multicenter studies with common PRO measurement protocols could allow for better understanding or correlates (e.g., sociodemographics) of PROs as they relate to treatment of HCC. There may be important subgroup differences of patient experience stratified by underlying liver disease, sex, racial/ethnic, or socioeconomic factors. Given that the comparative efficacy on disease control of many of the therapies for HCC is emerging, systematic measurement of PROs can provide essential insights regarding the relative efficacy and tolerability of HCC therapy. Given the recent approval of multiple systemic therapies, there is a fundamental need to understand the impact of therapy on PROs when designing patient-centered, personalized treatment plans. As shown with other cancers, routine clinical measurement of PROs in HCC may lead to improved outcomes as PROs may elicit symptoms or concerns not otherwise captured in a clinical encounter.^[77]

Second, the role of palliative care and other supportive care measures in PROs has not been systematically evaluated. Studies in other cancer types have shown that longitudinal HRQOL measurement in patients receiving palliative care can lead to referral for more aggressive symptom management.^[78] Patients undergoing noncurative HCC therapy, including locoregional therapy, have deteriorating PROs representing major unmet needs that could be addressed with palliative care (Figures 3 and 4). It is also important to note the variability in symptom trajectories based on patient selection, study setting, duration of follow-up, and PRO instrument selected. Given the current evidence, specific PRO instruments cannot be recommended; however, evidence supports short-term worsening of HRQOL secondary to treatment, which may be transient, and expectedly more sustained worsening with tumor and liver disease progression.

Third, these data highlight the complex interplay between HCC stage and therapy with psychosocial and behavioral factors in determining a patient's HRQOL. As such, optimal management will require a multidisciplinary and holistic approach integrating hepatology, primary care, oncology, interventional radiology, and other specialties. It is unclear whether contemporary liver cancer clinics are equipped to provide such care. Approaches to addressing patient well-being will vary with the stage of disease as well as the patient's psychosocial comorbidities. For example, early-stage disease may benefit from management with primary care, social work or psychiatry, and hepatology, whereas intermediate-stage to late-stage disease may benefit from palliative care playing a central role.^[79] Notably,

caregivers of patients with HCC are an understudied group who likely have unmet needs in our current paradigms of care.

Finally, the implementation of PRO assessment in clinical care requires additional study. Assessments can be conducted in clinics using paper-based surveys, but this requires dedicated staff to administer, collect, and enter the data. Using the model that we developed with PRO-based metrics for cirrhosis, we selected a limited set of PROs that could be administered through the electronic medical record.^[5] Electronic capture (e.g., patient completes assessment before appointment, while in waiting room, or at home in between treatments) is efficient and allows centers to regularly create reports for self-assessment and quality improvement. Design of PRO data capture, however, must account for patients with low health or digital literacy and limited English proficiency to avoid disparities in ascertainment. Studies will also need to assess how responses to those assessments may influence informed decision-making, treatment of symptoms, and advance care planning.

CONCLUSIONS

This scoping review has shown the breadth of the existing literature on PROs for HCC across the treatment continuum. We have highlighted several important findings and opportunities for future investigations. Further studies that integrate PROs into clinical practice and studies of comparative effectiveness of treatment impact on PROs across HCC stages will allow the development of robust quality of care indicators and enhance the quality of care for this group with high symptom burden and mortality. Although data are insufficient to recommend specific measures, evidence suggests that incorporating PRO measurement into clinical practice may reduce treatment-related anxiety, improve patient/ caregiver well-being, and guide clinical management.^[80]

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Funding information

Supported by the National Institutes of Health (1K23DK1158907-03, to M. S.; 1K23DK117055-01A1, to E. T.; and U01-CA-230669, U01-CA-230694, and 5R01CA222900, to N. P.) and by the Baylor Foundation (to S. K. A.)

Abbreviations:

AFP	alpha-fetoprotein
BCLC	Barcelona Clinic Liver Cancer
ECOG	Eastern Cooperative Oncology Group
EORTC	European Organization for Research and Treatment of Cancer
EQ-5D	EuroQol-5 Dimensions
FACT-Hep	Functional Assessment of Cancer Therapy, Hepatobiliary

FHSI-8	FACT Hepatobiliary Symptom Index-8
HCC-18	Hepatocellular Carcinoma-18
HRQOL	health-related quality of life
PRO	patient-reported outcome
QLQ-C30	Quality of Life Questionnaire Core-30
QOL	quality of life
RFA	radiofrequency ablation
SF-12/SF-36	Short Form 12/Short Form 36
TACE	transarterial chemoembolization
TARE	transarterial radioembolization
VAS	Visual Analogue Scale

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. [PubMed: 30207593]
- Li L, Yeo W. Value of quality of life analysis in liver cancer: a clinician's perspective. World J Hepatol. 2017;9:867–83. [PubMed: 28804570]
- Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M. The importance of patientreported outcomes in clinical trials and strategies for future optimization. Patient Related Outcome Measures. 2018;9:353. [PubMed: 30464666]
- Kanwal F, Tapper EB, Ho C, Asrani SK, Ovchinsky N, Poterucha J, et al. Development of quality measures in cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2019;69:1787–97. [PubMed: 30586188]
- Tapper EB, Kanwal F, Asrani SK, Ho C, Ovchinsky N, Poterucha J, et al. Patient reported outcomes in cirrhosis: a scoping review of the literature. Hepatology. 2018;67:2375–83. [PubMed: 29272043]
- 6. Feeny DH, Eckstrom E, Whitlock EP, Perdue LA. Patient-reported outcomes, health-related quality of life, and function: an overview of measurement properties. In A primer for systematic reviewers on the measurement of functional status and health-related quality of life in older adults. Rockville, MD: Agency for Healthcare Research and Quality. https://www.ncbi.nlm.nih.gov/books/ NBK169156/
- 7. Pose E, Trebicka J, Mookerjee RP, Angeli P, Ginès P. Statins: old drugs as new therapy for liver diseases? J Hepatol. 2019;70:194–202. [PubMed: 30075229]
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. [PubMed: 27919275]
- 9. Ryu E, Kim K, Cho MS, Kwon IG, Kim HS, Fu MR. Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma. Cancer Nurs. 2010;33:3–10. [PubMed: 19926981]
- Bianchi G, Loguercio C, Sgarbi D, Abbiati R, Brunetti N, De Simone T, et al. Reduced quality of life of patients with hepatocellular carcinoma. Dig Liver Dis. 2003;35:46–54. [PubMed: 12725608]
- Chung M-H, Wang S-Y, Lin C-C. Symptom clusters and impact of fatigue and sleep disturbance on symptom experiences of hepatoma patients in Taiwan. Cancer Nurs. 2017;40:403–11. [PubMed: 27472191]

- 12. Li L, Mo F, Hui EP, Chan SL, Koh J, Tang NLS, et al. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol. 2019;19:66. [PubMed: 31046687]
- Qiao CX, Zhai XF, Ling CQ, Lang QB, Dong HJ, Liu Q, et al. Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. World J Gastroenterol. 2012;18:2689–94. [PubMed: 22690079]
- Hsu W-C, Tsai AC, Chan S-C, Wang P-M, Chung N-N. Mini-nutritional assessment predicts functional status and quality of life of patients with hepatocellular carcinoma in Taiwan. Nutr Cancer. 2012;64:543–9. [PubMed: 22519878]
- Kondo Y, Yoshida H, Tateishi R, Shiina S, Mine N, Yamashiki N, et al. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:197–203. [PubMed: 17295871]
- Mikoshiba N, Miyashita M, Sakai T, Tateishi R, Koike K. Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on health-related quality of life. Psycho-Oncology. 2013;22:2347–53. [PubMed: 23686523]
- Lee H-H, Chiu C-C, Lin J-J, Wang J-J, Lee K-T, Sun D-P, et al. Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma. J Affect Disord. 2019;246:361–7. [PubMed: 30597297]
- Hansen L, Dieckmann NF, Kolbeck KJ, Naugler WE, Chang MF. Symptom distress in patients with hepatocellular carcinoma toward the end of life. Oncol Nurs Forum. 2017;44:665–73. [PubMed: 29052660]
- Fan SY, Eiser C, Ho MC, Lin CY. Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping. Psycho-Oncology. 2013;22:1353–60. [PubMed: 22847677]
- Steel JL, Chopra K, Olek MC, Carr BI. Health-related quality of life: hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res. 2007;16:203–15. [PubMed: 17119847]
- Steel J, Hess SA, Tunke L, Chopra K, Carr BI. Sexual functioning in patients with hepatocellular carcinoma. Cancer. 2005;104:2234–43. [PubMed: 16220558]
- 22. Palmieri VO, Santovito D, Margari F, Lozupone M, Minerva F, Di Gennaro C, et al. Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis. Clin Exp Med. 2015;15:65–72. [PubMed: 24323278]
- Moore AM, Gamblin TC, Geller DA, Youssef MN, Hoffman KE, Gemmell L, et al. A prospective study of posttraumatic growth as assessed by self-report and family caregiver in the context of advanced cancer. Psychooncology. 2011;20:479–87. [PubMed: 20878841]
- 24. Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouché O, Raoul JL, et al. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res. 2008;17:831–43. [PubMed: 18618292]
- Sternby Eilard M, Hagström H, Mortensen KE, Wilsgaard T, Vagnildhaug OM, Dajani O, et al. Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver Int. 2018;38:885–94. [PubMed: 28941130]
- Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751–5. [PubMed: 9731568]
- Gmür A, Kolly P, Knopfli M, Dufour JF. FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG performance status. Liver Int. 2018;38:1468–74. [PubMed: 29389088]
- 28. Li L, Mo FKF, Chan SL, Hui EP, Tang NSL, Koh J, et al. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma—clinical application of health-related quality-of-life data. BMC Cancer. 2017;17:8. [PubMed: 28052758]
- Kim G-A, Kim HI, Chang S, An J, Lee D, Lee HC, et al. A prospective evaluation of the reliability and utility of quality of life measures in patients with hepatocellular carcinoma. Am J Clin Oncol. 2019;42:555–63. [PubMed: 31135382]

- Deng Y, Zhu J, Liu Z, Huang M, Chang DW, Gu J. Elevated systemic inflammatory responses, factors associated with physical and mental quality of life, and prognosis of hepatocellular carcinoma. Aging (Albany NY). 2020;12:4357–70. [PubMed: 32145060]
- Meier A, Yopp A, Mok H, Kandunoori P, Tiro J, Singal AG. Role functioning is associated with survival in patients with hepatocellular carcinoma. Qual Life Res. 2015;24:1669–75. [PubMed: 25502092]
- 32. Gill J, Baiceanu A, Clark PJ, Langford A, Latiff J, Yang P-M, et al. Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. Future Oncol. 2018;14:1701–10. [PubMed: 29543521]
- Fan SY, Eiser C. Illness experience in patients with hepatocellular carcinoma: an interpretative phenomenological analysis study. Eur J Gastroenterol Hepatol. 2012;24:203–8. [PubMed: 22138684]
- Hansen L, Rosenkranz SJ, Vaccaro GM, Chang MF. Patients with hepatocellular carcinoma near the end of life: a longitudinal qualitative study of their illness experiences. Cancer Nurs. 2015;38:E19–27.
- Kaiser K, Mallick R, Butt Z, Mulcahy MF, Benson AB, Cella D. Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study. Support Care Cancer. 2014;22:919–26. [PubMed: 24258355]
- Lo SH, Sharma R, Costentin CE, Aggio D, Shergill S, Colaone F, et al. Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study. Future Oncol. 2021;17:4275–87. [PubMed: 34313150]
- 37. Lee E Relationships among depressive symptoms, spiritual well-being, and quality of life in primary liver cancer patients in Korea. Dissertation. Case Western Reserve University; 2012.
- 38. Patel N, Maher J, Lie X, Gwaltney C, Barzi A, Karwal M, et al. Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Qual Life Res. 2021. 10.1007/s11136-021-02903-4
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905. [PubMed: 32402160]
- 40. Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim T-Y, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:991– 1001. [PubMed: 34051880]
- 41. Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73. [PubMed: 29433850]
- Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:649– 58. [PubMed: 34087115]
- 43. Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, et al. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int. 2020;40:2008–20. [PubMed: 32279446]
- 44. Zhu AX, Nipp RD, Finn RS, Galle PR, Llovet JM, Blanc JF, et al. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patientreported outcomes across two randomised clinical trials. ESMO Open. 2020;5:e000797. [PubMed: 32817068]
- 45. Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6:e204564. [PubMed: 33001135]
- 46. Ryoo B-Y, Merle P, Kulkarni AS, Cheng A-L, Bouattour M, Lim HY, et al. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically

treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. Cancer. 2021;127:865–74. [PubMed: 33231873]

- 47. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624–36. [PubMed: 29107679]
- 48. Chow PKH, Gandhi M, Tan S-B, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913–21. [PubMed: 29498924]
- Brunocilla PR, Brunello F, Carucci P, Gaia S, Rolle E, Cantamessa A, et al. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2013;30:345. [PubMed: 23263829]
- Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11:1358–65.e1. [PubMed: 23644386]
- Poon RT, Fan ST, Yu WC, Lam BK, Chan FY, Wong J. A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg. 2001;136:693–9. [PubMed: 11387012]
- Huang G, Chen X, Lau WY, Shen F, Wang R-Y, Yuan S-X, et al. Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas. Br J Surg. 2014;101:1006–15. [PubMed: 24863168]
- 53. Wang Y-B, Chen M-H, Yan K, Yang W, Dai Y, Yin S-S. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res. 2007;16:389–97. [PubMed: 17111232]
- 54. Toro A, Pulvirenti E, Palermo F, Di Carlo I. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg Oncol. 2012;21:e23–30. [PubMed: 22104002]
- 55. Liu J, Wang Y, Zhang D, Liu B, Ou Q. Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastro Hepatol. 2012;24:186–94.
- 56. Chie W-C, Blazeby JM, Hsiao C-F, Chiu H-C, Poon RT, Mikoshiba N, et al. Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma. Asia Pac J Clin Oncol. 2017;13:e304–11. [PubMed: 27038366]
- 57. Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, et al. Healthrelated quality of life in patients with hepatocellular carcinoma treated with initial transarterial chemoembolization. Cardiovasc Intervent Radiol. 2017;40:1559–66. [PubMed: 28488104]
- Hartrumpf KJ, Marquardt S, Werncke T, Murray T, Kirstein MM, Vogel A, et al. Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC. J Cancer Res Clin Oncol. 2018;144:1991–9. [PubMed: 30008024]
- 59. Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer. 2017;81:17–25. [PubMed: 28591675]
- Cao W, Li J, Hu C, Shen J, Liu X, Xu Y, et al. Symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China. Support Care Cancer. 2013;21:475–83. [PubMed: 23010958]
- Lee L-H, Chen C-H, Yao G, Chung C-W, Sheu J-C, Lee P-H, et al. Quality of life in patients with hepatocellular carcinoma received surgical resection. J Surg Oncol. 2007;95:34–9. [PubMed: 17192864]
- 62. Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, et al. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol. 2010;21:1024–30. [PubMed: 20621715]

- 63. Chiu CC, Lee KT, Wang JJ, Sun DP, Lee HH, Huang CC, et al. Preoperative health-related quality of life predicts minimal clinically important difference and survival after surgical resection of hepatocellular carcinoma. J Clin Med. 2019;8:576. [PubMed: 31035539]
- 64. He Q, Jiang JJ, Jiang YX, Wang WT, Yang L. Health-related quality of life comparisons after radical therapy for early-stage hepatocellular carcinoma. Transplant Proc. 2018;50:1470–4. [PubMed: 29880373]
- 65. Shomura M, Kagawa T, Okabe H, Shiraishi K, Hirose S, Arase Y, et al. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. BMC Cancer. 2016;16:878. [PubMed: 27835949]
- 66. Shun SC, Chen CH, Sheu JC, Liang JD, Yang JC, Lai YH. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist. 2012;17:732–9. [PubMed: 22511265]
- 67. Hassanin TM, Fouad Y, Hassnine A, Eisawy M, Farag N, Abdel GW. Quality of life after transcatheter arterial chemoembolization combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma compared with transcatheter arterial chemoembolization alone. Asian Pac J Cancer Prev. 2021;22:1255–61. [PubMed: 33906320]
- 68. Loffroy R, Ronot M, Greget M, Bouvier A, Mastier C, Sengel C, et al. Short-term safety and quality of life outcomes following radioembolization in primary and secondary liver tumours: a multi-centre analysis of 200 patients in France. Cardiovasc Intervent Radiol. 2021;44:36–49. [PubMed: 32975600]
- 69. Pereira H, Bouattour M, Burgio MD, Assenat E, Grégory J, Bronowicki J-P, et al. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). Eur J Cancer. 2021;154:46–56. [PubMed: 34243077]
- 70. Salem R, Hassan S, Lewandowski RJ, Grace K, Martin RCG, Sichlau MJ, et al. Quality of life after radioembolization for hepatocellular carcinoma using a digital patient-reported outcome tool. J Vasc Interv Radiol. 2020;31:311–4 e311. [PubMed: 31732223]
- 71. Kirchner T, Marquardt S, Werncke T, Kirstein MM, Brunkhorst T, Wacker F, et al. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. Abdom Radiol (NY). 2019;44:1554–61. [PubMed: 30311050]
- 72. Iwata H, Ogino H, Hattori Y, Nakajima K, Nomura K, Hayashi K, et al. Image-guided proton therapy for elderly patients with hepatocellular carcinoma: high local control and quality of life preservation. Cancers (Basel). 2021;13:219. [PubMed: 33435340]
- 73. Gunsar F, Raimondo ML, Jones S, Terreni N, Wong C, Patch D, et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther. 2006;24:563–72. [PubMed: 16827812]
- 74. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217–32. [PubMed: 2646490]
- 75. Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy–hepatobiliary questionnaire. J Clin Oncol. 2002;20:2229–39. [PubMed: 11980994]
- 76. Blazeby JM, Currie E, Zee BC, Chie WC, Poon RT, Garden OJ. Development of a questionnaire module to supplement the EORTC QLQ-C 30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer. 2004;40:2439–44. [PubMed: 15519517]
- Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318:197–8. [PubMed: 28586821]
- Stukenborg GJ, Blackhall LJ, Harrison JH, Dillon PM, Read PW. Longitudinal patterns of cancer patient reported outcomes in end of life care predict survival. Support Care Cancer. 2016;24:2217– 24. [PubMed: 26573279]
- 79. Verma M, Tapper EB, Singal AG, Navarro V. Nonhospice palliative care within the treatment of end-stage liver disease. Hepatology. 2020;71:2149–59. [PubMed: 32167615]

 Denis F, Basch E, Septans AL, Bennouna J, Urban T, Dueck AC, et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA. 2019;321:306–7. [PubMed: 30667494]

QLQ-C30	QLQ-HCC18	FACT-G	FACT-HEP	FHSI-8	SF-36/SF-12
 Functioning Physical Role Cognitive Emotional Social Symptoms Fatigue Pain Nausea and vomiting Global health Overall QoL Additional items: Other symptoms Other problems 	 Fatigue Body image Jaundice Nutrition Pain Fever Other symptoms: Abdominal swelling Sex life 	 Physical well-being (PWB) Social/family well- being (SWB) Emotional well- being (EWB) Functional well- being (FWB) 	 Physical well-being (PWB) Social/family well- being (SWB) Emotional well- being (EWB) Functional well- being (FWB) Hepatobiliary cancer subscale (HCS) 	 Pain General Stomach pair/discomfort Back pain Lack of energy Fatigue Nausea Weight loss Jaundice 	 Physical functioning General health Mental health Vitality Role physical Role emotional Bodily pain Social functioning
EO	RTC		FACIT		Short Form
N	=23		N=19		N=10

FIGURE 1.

Most commonly used validated PRO questionnaires in HCC. FACIT, Functional Assessment of Chronic Illness Therapy; FACT-G, FACT–General; QLQ-HCC18, HCC-specific domain of QLQ




FIGURE 2.

Dominant themes elicited in qualitative studies

Serper et al.






FIGURE 3.

Changes in HRQOL over time in patients with HCC undergoing various treatment methods compared with baseline as Functional Assessment of Chronic Illness Therapy. FACT-G, FACT-General; HR, hepatic resection; Y90, 90-yttrium




FIGURE 4.

Changes in HRQOL over time in patients with HCC undergoing various treatment methods compared with baseline with (A) SF-12 or SF-36 and (B) EORTC. Ate, atezolizumab; Bev, bevacizumab; HR, hepatic resection; Len, lenvatinib; LT, liver transplantation

Baseline fact	Baseline factors associated with HRQOL in	with HRQO	oL in HCC	•					
References	PRO measure(s)	Cohort	Sample size	CTP class	Staging	Prior therapy?	Other notes	Aims	Prognostic factors for survival and/or changes in QOL
Bianchi et al. [10]	SF-36, NHP	(+): HCC	101	A (35%)	Not reported	Not reported	(+): cirrhosis	QOL in patients with cirrhosis + HCC	(+): age, male gender
				B (43%)			(+): HBV and/or HCV (75%)		(-): sleep disorders, daily medications, associated
				C (22%)			(+): comorbidity (64%)		diseases, HCC diameter
		:(+)	202	A (39%)	N/A	N/A	(+): cirrhosis		
		currhosis, (–): HCC		B (41%)			(+): HBV and/or HCV (69%)		
				C (20%)			(+): comorbidity (66%)		
Kondo et al. ^[15]	SF-36	(+): HCC	97	A (77%)	Not reported	(+:) PEIT or RFA	(+): recurrence (63%)	Comparison of HRQOL between patients with	(+): serum albumin, prothrombin activity
				B (21%)			(+): HBV (14%)	CLD with HCC + without HCC	(–): age (PCS), female sex
				C (2%)			(+): HCV (84%)		(PCS), presence of ascites (PCS), platelet count
		(+): CLD,	76	A (89%)	N/A	N/A	(+): HBV (10%)		
		(-): HCC		B (11%)			(+): HCV (88%)		
Hsu et al. ^[14]	EORTC QLQ- C30	N/A	300	A (67%)	AJCC I (7%), II (34%), III (42%), IV (16%)	Not reported	(+): HBV (54%)	QOL evaluation using nutrition-based instrument	(+): nutritional status, hemoglobin, albumin, self- rated health status, motility
				B (29%) C (3%)			(+): HCV (51%)		(-): turnor staging, CTP score, WBC
Li et al. ^[12]	EORTC QLQ- C30 and HCC-18	N/A	517	A (67%)	Not reported	None	(+): cirrhosis (59%)	Correlation between baseline QOL + liver function	(+): albumin, albumin-to- ALP ratio
				B (28%)			(+): HBV (82%)		(-): ALBI grade, ascites,
				C (5%)			(+): HCV (6%)		MELD,
Steel et al. ^[20]	FACT-Hep	(+): HCC	83	A (51%)	TNM I and II (20%),	None	(+): HBV (9%)	HRQOL comparison	N/A
				B (26%)			(+): HCV (30%)	general population	
				C (1%)					
		(+): CLD,	51	A (60%)	N/A	None	(+): HBV (4%)		
		(-). הרנ		B (30%)			(+): HCV (43%)		

Author Manuscript

TABLE 1

Author Manuscript

References	PRO measure(s)	Cohort	Sample size	CTP class	Staging	Prior therapy?	Other notes	Aims	Prognostic factors for survival and/or changes in QOL
				C (10%)					
Ryu et al. ^[9]	FACT-Hep, HADS, Korean	(+): HCC	180	A (83%)	9% with metastatic disease	Not reported	(+): HBV (81%)	Identify symptom clusters; association	(+): anxiety, depression
	HCC symptom checklist			B (16%)			(+): HCV (11%)	between symptom clusters and HRQOL	
				C (1%)					
Qiao et al. ^[13]	FACT-Hep	N/A	140	A (60%)	TNM I (35%), II	None	(+): cirrhosis	QOL changes by TNM	(-): TNM stage
				B (21%)	(22%), IIIA (21%), IIIB (19%)		(+): HBV (97%)	staging	
				C (19%)			(+): HCV (1%)		
Chung et al. ^[11] MDASI-T	MDASI-T	N/A	100	A (48%)	TNM I (16%), II (31%), III (45%), IV	RT (30%)	(+): metastasis (92%)	Symptom cluster analysis; impact of sleep/fatigue on	(–): fatigue, sleep disturbance
				B (33%)	(8%)	TAE (29%)		symptoms	
				C (19%)		PEIT (24%)			

international normalized ratio; MDASI-T, MD Anderson Symptom Inventory (Taiwanese version); MELD, Model for End-Stage Liver Disease; N/A, not available; NHP, Nottingham Health Profile; PEIT, Abbreviations: AJCC, American Joint Committee on Cancer Staging; ALBI, albumin-bilirubin grade; ALP, alkaline phosphatase; ALT, alanine aminotransferase; CLD, chronic liver disease; CRP, C-reactive protein; CTP, Child-Turcotte-Pugh (score or class); GGT, gamma-glutamyl transpeptidase; HADS, Hospital Anxiety and Depression Scale; PCS, physical component score (SF); INR, percutaneous ethanol injection therapy; RT, radiation therapy; TAE, transarterial embolization; TNM, tumor-node-metastasis; WBC, white blood cells.

Hepatology. Author manuscript; available in PMC 2023 November 15.

Author Manuscript

	Prognostic factors for survival and/or changes in QOL	(–): depression, somatization, anxiety	(–): depression, somatization,	 (+): problem- oriented coping, understanding, emotional functioning, physical functioning; 	(–): ECOG PS, AFP levels, negative	QOL: (-): depressive symptoms	Depressive symptoms: (+): KPS;	 (-): CTP score, living alone, unemployment 	(-): sexual problems							No associations between PTG and HRQOL
	Aims	Development of behavioral + psychopathological profile of HCC, association with prognostics	100 +	Characterization of QOL in HCC, physical + psychological predictors of QOL		Association of depressive symptoms + QOL, characterization in HCC survivors			Evaluation of sexual morbidities in HCC population							Association of PTG and HRQOL, depressive symptoms
	Other notes	(+): HBV (27%) (+): HCV (64%)	(+): HBV (17%) (+) HCV (79%)			(+): HBV (34%)	(+): HCV (59%)	(+): comorbidity (65%)	Entirely men	(+): cirrhosis (84%)	(+): HBV (13%)	(+): HCV (44%)	Entirely men	(+): cirrhosis (88%)	(+): HCV (57%)	(+): cirrhosis (78%)
	Prior therapy?	Not reported	Not reported	HR (41%), TACETAE (34%), chemotherapy (26%)		Curative treatment			Not reported							Chemotherapy (70%), surgery (14%),
	Staging	N/A	BCLC A (71%), B (17%), D (13%)	AJCC 1 (38%), 2 (23%), 3 (30%), 4 (4%)		Not reported			TNM III (5%), IV (95%)				N/A			Not reported
,	CTP class	A (91%) B (9%)	A (88%) B (12%)	A (78%)	B (15%) C (6%)	A (76%)	B and C (24%)		A (73%)	B (18%)			A (67%)	B (27%)	C (6%)	Not reported
	Sample size	22	24	286		128			21				23			202, 67% +HCC
	Cohort	(+): cirrhosis	(+): HCC	N/A		N/A			(+): HCC				(+): CLD			(+): hepatobiliary malignancy
	PRO measure(s)	SF-36, SCL-90- R, TAS-20, Hamilton-D		EORTC QLQ- C30		EORTC QLQ- C30 and HCC-18			FACT-Hep, sexual history questionnaire							FACT-Hep, CES-D, PTG
5	References	Palmieri et al. [22]		Fan et al. ^[19]		Mikoshiba et al. ^[16]			Steel et al. ^[21]							Moore et al. [23]

Author Manuscript

TABLE 2

Psychosocial and psychological factors associated with HRQOL in HCC

Prognostic factors for survival and/or changes in QOL	(-): anxiety, depression		N/A
Aims	Longitudinal effects of anxiety + depression in patients with HCC following resection		Longitudinal assessment of symptom distress in advanced HCC population
Other notes	(+): cirrhosis (40%)	(+) HBV (28%) (+) HCV (16%)	(+): HBV (6%) (+): HCV (61%)
Prior therapy? combination (8%), no treatment (8%)	Chemotherapy (3%)	Radiotherapy (1%)	Not reported
Staging	TNM I (57%), II (27%), III&IV (16%)		Not reported
CTP class	Not reported		Not reported
Sample size	410		18
Cohort	N/A		(+): HCC
PRO measure(s)	FACT-Hep, BAI, N/A BDI		MSAS
References	Lee et al. ^[17]		Hansen et al. [18]

Abbreviations: AJCC, American Joint Committee on Cancer Staging; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CES-D, Center for Epidemiological Studies Depression Scale; CLD, chronic liver disease; CTP, Child-Turcotte-Pugh (score or class); Hamilton-D, Hamilton Depression rating scale; HR, hepatic resection; KPS, Kamofsky performance score; MSAS, Memorial Symptom Assessment Scale; N/A, not available; PS, performance status; PTG, post-traumatic growth; SCL-90-R, Symptom Checklist 90-R; TAE, transarterial embolization; TAS-20, Toronto Alexithymia Scale; TNM, tumor–node–metastasis.

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 3

Author Manuscript

Author Manuscript

_
_
_
_
_
\sim
\mathbf{O}
-
<
0
2
_
-
C
CD .
~
0
~
\mathbf{U}
–

Au	
thor	
Mar	
nusc	
ript	

Proposed prognostic factors for survival	Both components: (–): abnormal WBC counts, high NLR, low albumin	Improvement of (+): Spitzer score, albumin, small prognostication with HCC QøL	(-): jaundice, hepatomegaly, hepatalgia, ascites, PVT,	
Aims		Improve prognosi QøL		
Other notes		Palliative HCC	(+): cirrhosis (93%)	
Prior therapy?		Not reported		
Staging		BCLC A (3%), B (13%), C (76%), D (8%);	Okuda 1 (41%), 2 (52%), 3 (7%)	
CTP class		A (57%)	B (40%)	C (3%)
Sample size		538		
PRO measure(s)		Spitzer QOL index		
References		Bonnetain et al. Spitzer QOL [24] index		

resection; LMR, lymphocytes-to-monocytes ratio; LT, liver transplantation; MCS, mental component score; NLR, neutrophils-to-lymphocyte ratio; PCS, physical component score; PS, performance status; PVT, portal vein thrombosis; SIRT, selective internal radiation therapy; TNM, tumor-node-metastasis; WBC, white blood cells. Abbreviations: ALP, alkaline phosphatase; CLIP, Cancer of the Liver Italian Program staging; CTP, Child-Turcotte-Pugh (score); FACT-G, FACT-General; HBS, hepatobiliary subscale; HR, hepatic

C the	Effects of HCC therapy on HRQOL	IRQOL							Prognostic
PRO measure(s)		Therapy	Sample size	CTP class	Staging	Prior therapy?	Other notes	Aims	factors for survival and/or changes in QoL
EORTC QLQ- C30 + HCC-18		TARE/SIRT	237	A (83%)	BCLC A (4%), B (28%), C (68%)	TACE (45%)	(+): cirrhosis (89%)	Safety and efficacy comparison between	N/A
				B (16%)			(+): HBV (5%)	soratenib and SIK1 with Y90 microspheres	
							(+) HCV (23%)		
		Sorafenib	222	A (84%)	BCLC A (5%), B (27%), C (67%)	TACE (42%)	(+): cirrhosis (91%)		N/A
				B (16%)			(+): HBV (7%)		
							(+): HCV (22%)		
EORTC QLQ- C30 + HCC-18		Lenvatinib	478	A (99.4%)	BCLC B (21.8%), C (78.2%)	Yes (68.4%)	(+): cirrhosis (74.5%)	Survival comparison between lenvatinib and	(+): AFP levels
				B (0.6%)			(+): HBV (52.5%)	sorarenib	
							(+): HCV (19.0%)		
		Sorafenib	476	A (98.9%)	BCLC B (19.3%), C (80.7%)	Yes (72.3%)	(+): cirrhosis (76.5%)		(+): AFP levels
				B (1.1%)			(+): HBV (47.9%)		
							(+): HCV (26.5%)		
EORTC QLQ- C30		Atezolizumab + bevacizumab	336	A5 (72%)	BCLC A (2%), B (15%), C (82%)	Local therapy	(+): HBV (49%)	Safety and efficacy of atezolizumab + bevacizumab	N/A
				A6 (28%)		(48%)	(+): HCV (21%), nonviral etiology (30%)		
		Sorafenib	165	A5 (73%)	BCLC A (4%), B	Local	(+): HBV (46%)		N/A
				A6 (27%)	(10%), U (01%)	unerapy (52%)	(+): HCV (22%), nonviral etiology (32%)		
EORTC QLQ- C30 + HCC-18	$\frac{18}{18}$	Lenvatinib	478	A (99.4%)	BCLC B (21.8%), C (78.2%)	Yes (68.4%)	(+): cirrhosis (74.5%)	HRQOL comparison between lenvatinib and	(+): responders
				B (0.6%)			(+): HBV (52.5%)	soratenib	
							(+): HCV (19.0%)		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 4

=
-
<u>≍</u>
0
~
CO CO
=
~~~
Š.
$\mathbf{O}$
0
t

Prognostic factors for survival and/or changes in Ool.	(+): responders			N/A	N/A	N/A			N/A			N/A		N/A		N/A		N/A		N/A		N/A		N/A	
Aims				HRQOL comparison between atezolizumab +	Devaciumad and soratenid	Longitudinal HRQOL	pembrolizumab and PBO					HRQOL + PS evaluation	arter ramucuruman merapy			HRQOL evaluation for	ramucirumao inerapy			Evaluation of safety and	erncacy of ramucirumab			Evaluation of safety and	erncacy or SIK1 and sorafenib
Other notes	(+): cirrhosis (76.5%)	(+): HBV (47.9%)	(+): HCV (26.5%)			(+): HBV (25.9%)	(+): HCV (15.5%)		(+): HCV (21.5%)	(+): HCV (15.6%)		(+): HCV (27.2%)	(+): HBV (27.3%)	(+): HCV (35.3%)	(+): HBV (35.8%)	(+): HBV (39.2%)	(+): HCV (26.3%)	(+): HBV (45.1%)	(+): HCV (24.8%)	(+): HBV (39.2%)	(+): HCV (26.3%)	(+): HBV (45.1%)	(+): HCV (24.8%)	(+): HBV (51.1%)	(+): HCV (14.3%)
Prior therany?	Yes (72.3%)			Treatment- naive		Prior sorafanih	therapy					Prior	soratento therapy			Prior	sorarento therapy			Prior	sorarenib therapy			Not reported	
Staoine	BCLC B (19.3%), C (80.7%)			Not reported	Not reported	BCLC B (20.1%), C (70.0%)			BCLC B (21.5%),	(%C.8/) )		BCLC B (12%), C	(000)	BCLC B (12%), C	(88%)	BCLC B (14.2%),	U (00.0%)	BCLC B (12.8%),	L (81.2%)	BCLC B (14.2%),	C (85.8%)	BCLC B (12.8%),	C (81.2%)	BCLC A (0%), B	(48.4%) (48.4%)
CTP class	A (98.9%)	B (1.1%)		Not reported	Not reported	A5 (63.3%)	A6 (36.3%)	B (0.4%)	A5 (63.7%)	A6 (34.8%)	B (1.5%)	A (98%)	B and C (2%)	A (98%)	B and C (2%)	A (60.1%)		A (59.7%)		A (60.1%)		A (59.7%)		A (90.7%)	B (7.7%)
Sample size	476			336	165	271			127			283		282		316		226		316		226		182	
Therany	Sorafenib			Atezolizumab + bevacizumab	Sorafenib	Pembrolizumab			PBO			Ramucirumab	(111)	PBO (ITT)		Ramucirumab		PBO		Ramucirumab		PBO		SIRT	
PRO measure(s)				EORTC QLQ- C30 + HCC-18		EORTC QLQ- C30 ± HCC_18						FHSI-8	EQ-5D	EQ-5D-VAS		FHSI-8	EQ-5D			FHSI-8				EQ-5D	
References				Galle et al. ^[40]		Ryoo et al. ^[46]						Chau et al. ^[59]				Zhu et al. ^[44]				Kudo et al. ^[43]				Chow et al. ^[48]	

(+): HBV + HCV (2.2%)

Prognostic factors for survival and/or changes in QoL	N/A	N/A	N/A	N/A		(+): previous curative therapy, physical and social functioning	(–): vascular invasion, CTP, DCP	(+): education level, BMI, HRQOL subscale score;	(–): comorbidities	N/A	N/A	N/A
Aims		Evaluation of safety and efficacy of NV + IP in advanced HCC				Longitudinal HRQOL after sorafenib, prognostic factors		HROOL after resection, domain MCIDs, prognostic factors		Longitudinal HRQOL after first TACE	HRQOL comparison between transplant, resection, and RFA	
Other notes	(+): HBV (56.4%) (+): HCV (10.7%) (+): HBV + HCV (2.8%)	(+): HBV (56%) (+): HCV (14%)	(+): HBV (43%) (+): HCV (29%)	(+): HBV (53%) (+): HCV (24%)		(+): HCV (44%)	(+): HBV (20%)				(+): HBV (82%)	(+): HBV (87%)
Prior therapy?	Not reported	Prior sorafenib therapy				Yes (91%)		Yes (4%)		None	None	
Staging	BCLC A (0.6%), B (54.5%), C (44.9%)	BCLC 0 (2%), A (4%), B (8%), C (86%)	BCLC 0 (0%), A (0%), B (8%), C (92%)	BCLC 0 (0%), A (0%), B (6%), C		TNM III (43%), IV (57%)		TNM I (59%), II (28%), III (14%)		Okuda 1 (55%), 2 (42%), 3 (3%)	Not reported	
CTP class	A (89.9%) B (9.0%)	A (100%)	A (96%)	A (96%)		A (76%)	B (24%)	Not reported		A (47%) B (51%) C (3%)	A (27%) B (36%) C (36%)	A (88%) B (12%)
Sample size	178	50	49	49		54		369		73	22	68
Therapy	Sorafenib	NV (1 mg/kg) + IP (3 mg/kg) every 3 weeks, then NV (240 mg) every 2 weeks	NV (3 mg/kg) + IP (1 mg/kg) every 3 weeks, then NV (240 mg) every 2 weeks	NV (3 mg/kg) every 2 weeks		Sorafenib		Resection		TACE	Transplant	Resection
PRO measure(s)		EQ-5D-3L			ance	SF-36		SF-36	FACT-Hep	SF-36	SF-36	
References		Yau et al. ^[45]		:	Real-world evidence	Shomura et al. [65]		Chiu et al. ^[63]		Wible et al. ^[62]	He et al. ^[64]	

Prognostic factors for survival and/or changes in QoL	N/A	PCS: (+): age, recurrent disease	MCS: (-): male, recurrent disease	(+): female sex, primary tumor	(–): ECOG PS, CTP score, high	(+): resection			N/A		N/A		N/A		(+): symptom score	(–): MELD, CTP, ECOG PS, GHS, and functional scores	(+): symptom score
Aims		Longitudinal HRQOL after first TACE, prognostic	lactors	Safety and efficacy of IGPT in elderly cohort		Longitudinal HRQOL and	SULVIVAL		Longitudinal HRQOL comparison between	tesecuon + KFA + 1ACE; domain MIDs					HRQOL after first TACE, prognostic factors		HRQOL after repetitive TACE, prognostic factors
Other notes	(+): HBV (82%)	(+): HCV (39%)	(+): HBV (63%)	(+): HBV (10%)	(+): HCV (39%)	(+): HCV (42%)	(+): HBV (64%)	(+): cirrhosis (57%)	(+): cirrhosis (64%)	(+): comorbidity (51%)	(+): cirrhosis (81%)	(+): comorbidity (79%)	(+): cirrhosis (68%)	(+): comorbidity (60%)			(+): HCV (30%)
Prior therapy?		Yes (69%)		Yes (35%)		Not reported			Yes (28%)		Yes (70%)		Yes (69%)		None		None
Staging		BCLC A (46%), B (47%), C (7%)		BCLC 0 (10%), A (63%), B (2%), C (21%), D (4%)	TNM I (82%), II (15%), III (3%);	Not reported			BCLC A (91%), B&C (9%)		BCLC A (58%), B&C (42%)		BCLC A (37%), B and C (63%)		Not reported		Not reported
CTP class	A (47%) B (50%) C (3%)	A (90%)	B (10%)	A5 (69%)	A6 (21%) B (10%)	A (93%)	B (5%)	C (2%)	A (92%)	B and C (8%)	A (70%)	B and C (30%)	A (75%)	B and C (25%)	A (76%)	B (19%)	A (74%)
Sample size	38	89		71		161			53		53		65		79		148
Therapy	RFA	TACE		IGPT		Resection			Resection		RFA		TACE		TACE		TACE
PRO measure(s)		SF-12	SDS, HADS	EORTC QLQ- C30 and HCC-18	SF-36	EORTC QLQ-	WHOQOL-	BREF, VAS	EORTC QLQ- C30 + HCC-18						EORTC QLQ- C30 + HCC-18		EORTC QLQ- C30 + HCC-18
References		Shun et al. ^[66]		Iwata et al. ^[72]		Lee et al. ^[61]			Chie et al. ^[56]						Hinrichset al. [57]		Hartrumpf et al. ^[58]

Serper et al.

Prognostic factors for survival and/or changes in QoL (-): GHS and functional scores	<ul><li>(+): less fever</li><li>(-): female sex</li></ul>	(–): female sex, higher age	N/A	N/A	(+): low tumor burden	(+): low tumor burden	A/A	N/A
Aims	HRQOL comparison between TACE and TARE for unresectable HCC		HRQOL comparison between TACE and TACE + RFA		HRQOL comparison between TARE and sorafenib		Evaluation of safety and HRQOL after TARE with Y90 microspheres	Feasibility of sorafenib during 2-month treatment
Other notes (+): HBV (18%)	<ul> <li>(+): cirrhosis</li> <li>(56.5%)</li> <li>(+): HBV (4.3%)</li> <li>(+): HCV (17.4%)</li> </ul>	<ul> <li>(+): cirrhosis</li> <li>(47.6%)</li> <li>(+): HBV (9.5%)</li> <li>(+): HCV (14.3%)</li> </ul>	Post-HCV (64%) HCV + HBV (3%)		<ul> <li>(+): cirrhosis</li> <li>(89.3%)</li> <li>(+): HBV (3.3%)</li> <li>(+): HCV (18.0%)</li> </ul>	<ul> <li>(+): cirrhosis</li> <li>(90.2%)</li> <li>(+): HBV (4.9%)</li> <li>(+): HCV (21.5%)</li> </ul>	<ul> <li>(+): cirrhosis</li> <li>(71%)</li> <li>(+): HBV 2.5%)</li> <li>(+): HCV (23.5%)</li> </ul>	<ul> <li>(+): cirrhosis</li> <li>(92%)</li> <li>(+): HCV (47%)</li> <li>(+): HBV (11%)</li> </ul>
Prior therapy?	Treatment- naive	Treatment- naive	Not reported	Not reported	TACE (53%)	TACE (45%)	Yes (54.5%)	Yes (69%)
Staging	Not reported	Not reported	All BCLC B	All BCLC B	BCLC A (4%), B (31%), C (65%)	BCLC A (4%), B (26%), C (69%)	Not reported	BCLCB (8%), C (92%)
<b>CTP class</b> B and C (26%)	A (78.3%) B (21.7%)	A (85.7%) B (14.3%)	A (26.6%) B (60%) C (13.4%)	A (22.4%) B (64.3%) C (14.3%)	A5+6 (86%) B (13%)	A5 + A6 (91%) B (9%)	Not reported	A (100%)
Sample size	47	27	45	28	122	136	200 (114 HCC)	36
Therapy	TACE	TARE	TACE	TACE + RFA	TARE	Sorafenib	TARE + SIR	Sorafenib
PRO measure(s)	EORTC QLQ- C30 + HCC-18		EORTC QLQ- C30 + HCC-18		EORTC QLQ- C30		EORTC QLQ- C30 + HCC-18	FACT-Hep FHSI-8
References	Kirchner et al. [71]		Hassanin et al. [67]		Pereira et al. [69]		Loffroy et al. [68]	Brunocilla et al. ^[49]

Serper et al.

Prognostic factors for survival and/or changes in QoL	N/A		N/A		(–): TNM staging, recurrent	disease	N/A	(+): antiviral treatment	(–): cirrhosis, comorbidities					(+) income;	(–): recurrent disease, posttreatment CTP	(+): age	(-): recurrent disease, posttreatment CTP
Aims	HRQOL comparison between TARE + TACE				Longitudinal HRQOL evaluation after resection			Longitudinal HRQOL + survival comparison between	resection + KFA					HRQOL comparison between TACE alone and	IACE + KFA		
Other notes					(+): cirrhosis (41%)	(+): comorbidity (27%)	Inoperable HCC	(+): HBV	(+): cirrhosis (79%)	(+): comorbidity (23%)	(+): HBV	(+): cirrhosis (88%)	<ul><li>(+) co-morbidity</li><li>(18%)</li></ul>	(+): comorbidity (73%)		(+): comorbidity (56%)	
Prior therapy?	None				Yes (69%)		Not reported	None						None		None	
Staging	BCLC A (21%), B (41%), C (38%)	UNOS T1–3 (41%) T4a+ (59%)	BCLC A (56%), B (30%), C (14%);	UNOS T1–3 (74%), T4a+ (26%)	TNM I (3%), II (44%), III (47%),	IV (6%)	Not reported	BCLC A						TNM I and II (48%), III (13%),	IV (40%)	TNM I and II (49%), III (7%),	IV (44%)
CTP class	A (86%)	B (14%)	A (85%)	B (15%)	A (94%)	B and C (6%)	Not reported	Not reported						A (80%)	B (20%)	A (79%)	<b>B</b> (21%)
Sample size	29		27		99		10	121			225			40		43	
Therapy	TARE (Y-90)		TACE		Resection		TACE	RFA			Resection			TACE		TACE + RFA	
PRO measure(s)	FACT-Hep				FACT-G			FACT-Hep						FACT-G			
References	Salem et al. ^[50]				Poon et al. ^[51]			Huang et al. [52]						Wang et al. ^[53]			

Serper et al.

Auth
hor M
anusc
cript

Author Manuscript

Author	
Manuscr	
ipt	

Prognostic factors for survival and/or changes in QoL														
Prog facto survi chan	N/A		N/A		N/A		N/A		N/A				N/A	N/A
Aims	Longitudinal HRQOL	therapies							Comparison of outcomes, survival, and HRQOL	between HK + thrombectomy and	chemotherapy		Efficacy of an automated digital patient engagement platform	Cross-sectional symptom PCA after first TACE
Other notes	(+): HCV (93%)	(+): HBV (7%)	(+): HCV (87%)	(+): HBV (13%)	(+): HCV		(+): HCV (92%)	(+): HBV (8%)						
Prior therapy?	Not reported								Not reported				Not reported	None
Staging	Not reported								BCLC C				Not reported	BCLC A (27%), B (41%), C (32%)
CTP class	A (100%)		A (60%)	<b>B</b> (40%)	A (22%)	B (78%)	A (23%)	B (77%)	A and B (76%)	C (24%)	A and B (75.4%)	C (24.6%)	Not reported	A (94%) D (6%)
Sample size	14		15		6		13		65		50		40	155
Therapy	Resection		TACE		RFA		Best supportive	care	Resection + thrombectomy		Chemotherapy		TARE (Y-90)	TACE
PRO measure(s)	FACT-Hep								FACT-Hep				FHSI-8 with 7 questions from FACT-Hep	MDASI
References	Toro et al. ^[54]								Liu et al. ^[55]				Salem et al. ^[70]	Cao et al. ^[60]

status; HADS, Hospital Anxiety and Depression Scale; HR, hepatic resection; IGPT, image-guided proton therapy; IP, ipillumumab; ITT, intention to treat; MCID, minimal clinically important difference; Abbreviations: BMI, body mass index; CTP, Child-Turcotte-Pugh (score); DCP, des-gamma carboxyprothrombin; EQ-5d-3L, three-level version of EQ-5D; FACT-G, FACT-General; GHS, global health nivolumab; PBO, placebo; PCA, principal component analysis; PCS, Physical Component Summary (score); PIVKA-II, protein-induced by vitamin K absence or antagonist-II; PS, performance status; MCS, Mental Component Summary (score); MDASI, MD Anderson Symptom Inventory; MELD, Model for End-Stage Liver Disease; MID, minimally important difference; N/A, not available; NV, SDS, Symptom Distress Scale; SIR, systemic inflammatory response; SIRT, selective internal radiation therapy; TNM, tumor-node-metastasis; UNOS, United Network for Organ Sharing T staging; WHOQOL-BREF, World Health Organization Quality of Life Instrument, Short Form.

B (6%)